company background image
BNN

BRAIN Biotech XTRA:BNN Stock Report

Last Price

€8.00

Market Cap

€174.8m

7D

-3.4%

1Y

-18.4%

Updated

29 Jun, 2022

Data

Company Financials +
BNN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

BNN Stock Overview

BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom.

BRAIN Biotech Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BRAIN Biotech
Historical stock prices
Current Share Price€8.00
52 Week High€11.00
52 Week Low€7.38
Beta1.44
1 Month Change0.25%
3 Month Change-8.05%
1 Year Change-18.37%
3 Year Change-19.19%
5 Year Change-56.10%
Change since IPO-12.07%

Recent News & Updates

Shareholder Returns

BNNDE ChemicalsDE Market
7D-3.4%-3.3%-1.3%
1Y-18.4%-27.8%-22.2%

Return vs Industry: BNN exceeded the German Chemicals industry which returned -26.1% over the past year.

Return vs Market: BNN exceeded the German Market which returned -21.5% over the past year.

Price Volatility

Is BNN's price volatile compared to industry and market?
BNN volatility
BNN Average Weekly Movement5.5%
Chemicals Industry Average Movement5.8%
Market Average Movement5.6%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.9%

Stable Share Price: BNN is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: BNN's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993310Aryan Moelkerhttps://www.brain-biotech.com

BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates in two segments, BioScience and BioIndustrial. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and nature-based active ingredients for product development in the food, animal feed, skin care, cosmetics, and chemical industries.

BRAIN Biotech Fundamentals Summary

How do BRAIN Biotech's earnings and revenue compare to its market cap?
BNN fundamental statistics
Market Cap€174.78m
Earnings (TTM)-€7.64m
Revenue (TTM)€44.48m

3.9x

P/S Ratio

-22.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BNN income statement (TTM)
Revenue€44.48m
Cost of Revenue€19.15m
Gross Profit€25.33m
Other Expenses€32.97m
Earnings-€7.64m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 29, 2022

Earnings per share (EPS)-0.35
Gross Margin56.95%
Net Profit Margin-17.18%
Debt/Equity Ratio5.5%

How did BNN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BNN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BNN?

Other financial metrics that can be useful for relative valuation.

BNN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.7x
Enterprise Value/EBITDA-80.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does BNN's PS Ratio compare to its peers?

BNN PS Ratio vs Peers
The above table shows the PS ratio for BNN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average0.6x
2HRA H&R GmbH KGaA
0.2x7.6%€214.4m
ACT AlzChem Group
0.5x6.3%€204.7m
NTG Nabaltec
1.2x8.6%€235.8m
UZU Uzin Utz
0.7x6.1%€290.6m
BNN BRAIN Biotech
3.9x13.5%€174.8m

Price-To-Sales vs Peers: BNN is expensive based on its Price-To-Sales Ratio (3.9x) compared to the peer average (0.6x).


Price to Earnings Ratio vs Industry

How does BNN's PE Ratio compare vs other companies in the European Chemicals Industry?

Price-To-Sales vs Industry: BNN is expensive based on its Price-To-Sales Ratio (3.9x) compared to the German Chemicals industry average (1x)


Price to Sales Ratio vs Fair Ratio

What is BNN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BNN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.9x
Fair PS Ratio1.5x

Price-To-Sales vs Fair Ratio: BNN is expensive based on its Price-To-Sales Ratio (3.9x) compared to the estimated Fair Price-To-Sales Ratio (1.5x).


Share Price vs Fair Value

What is the Fair Price of BNN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BNN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BNN's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BNN's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is BRAIN Biotech forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


77.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BNN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.05%).

Earnings vs Market: BNN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BNN is expected to become profitable in the next 3 years.

Revenue vs Market: BNN's revenue (13.5% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: BNN's revenue (13.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BNN's Return on Equity is forecast to be low in 3 years time (12.2%).


Discover growth companies

Past Performance

How has BRAIN Biotech performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


10.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BNN is currently unprofitable.

Growing Profit Margin: BNN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BNN is unprofitable, but has reduced losses over the past 5 years at a rate of 10.2% per year.

Accelerating Growth: Unable to compare BNN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BNN is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (40.7%).


Return on Equity

High ROE: BNN has a negative Return on Equity (-20.98%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is BRAIN Biotech's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BNN's short term assets (€35.0M) exceed its short term liabilities (€13.5M).

Long Term Liabilities: BNN's short term assets (€35.0M) exceed its long term liabilities (€32.9M).


Debt to Equity History and Analysis

Debt Level: BNN has more cash than its total debt.

Reducing Debt: Insufficient data to determine if BNN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BNN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: BNN has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 4.6% each year.


Discover healthy companies

Dividend

What is BRAIN Biotech current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BNN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BNN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BNN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BNN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BNN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Aryan Moelker

2.33yrs

Tenure

€957,000

Compensation

Mr. Adriaan Moelker, also known as Aryan, has been Chairman of the Management Board and Chief Executive Officer of BRAIN Biotech AG (formerly known as B.R.A.I.N. Biotechnology Research and Information Netw...


CEO Compensation Analysis

Compensation vs Market: Aryan's total compensation ($USD1.00M) is above average for companies of similar size in the German market ($USD682.03K).

Compensation vs Earnings: Aryan's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: BNN's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: BNN's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21%.


Top Shareholders

Company Information

BRAIN Biotech AG's employee growth, exchange listings and data sources


Key Information

  • Name: BRAIN Biotech AG
  • Ticker: BNN
  • Exchange: XTRA
  • Founded: 1993
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Implied Market Cap: €174.780m
  • Shares outstanding: 21.85m
  • Website: https://www.brain-biotech.com

Number of Employees


Location

  • BRAIN Biotech AG
  • Darmstädter Strasse 34-36
  • Zwingenberg
  • Hessen
  • 64673
  • Germany

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/29 00:00
End of Day Share Price2022/06/29 00:00
Earnings2022/03/31
Annual Earnings2021/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.